Skip to main
MBOT

Microbot Medical (MBOT) Stock Forecast & Price Target

Microbot Medical (MBOT) Analyst Ratings

Based on 4 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Microbot Medical is a medical device company with a unique and innovative LIBERTY Endovascular Robotic Surgical System that is expected to experience high growth in the coming years. The company has a strong financial position with significant cash reserves and no debt, providing a solid foundation for commercializing its product. While there is some manufacturing concentration risk through its contract partners in Israel, this is mitigated by the company's plans to expand into additional manufacturing facilities. The recent system-level approvals at major hospitals demonstrate the effectiveness of the product and its potential for wide adoption, and any potential reimbursement risks can be managed through the existing reimbursement codes.

Bears say

Microbot Medical is experiencing slow adoption of its LIBERTY Endovascular Robotic Surgical System, with only 10-11 accounts and 15 hospitals currently using the system, resulting in a lower than expected revenue of $241K in 2Q26. Additionally, the company's expansion into coronary and neurovascular applications will require additional regulatory submissions and associated clinical data requirements, adding to uncertainty and potential delays. The recent limited market release and full market release at the SIR annual scientific meeting show promising adoption and potential for growth, but the addressable market of 2.5M peripheral endovascular procedures in the U.S may be limited. The stock remains a risky investment due to slow adoption, regulatory uncertainties, and limited market potential, therefore a negative outlook is warranted.

Microbot Medical (MBOT) has been analyzed by 4 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Microbot Medical and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Microbot Medical (MBOT) Forecast

Analysts have given Microbot Medical (MBOT) a Strong Buy based on their latest research and market trends.

According to 4 analysts, Microbot Medical (MBOT) has a Strong Buy consensus rating as of Aug 27, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $6.38, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $6.38, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Microbot Medical (MBOT)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.